Document Detail

Enalapril: benefit-to-risk ratio in hypertensive patients.
MedLine Citation:
PMID:  1691415     Owner:  NLM     Status:  MEDLINE    
Enalapril is an effective agent in the treatment of mild to severe hypertension. It is equally effective in elderly and young adult patients but appears to be more effective in white than in black hypertensive patients. Following treatment with enalapril, an assessment of maximum exercise performance found a decrease in total peripheral resistance without significant changes in cardiac output, heart rate, or stroke volume compared with pretreatment values. In addition, there have been reports of reversal of left ventricular hypertrophy in enalapril-treated hypertensive patients. Enalapril is also effective and well tolerated in hypertensive patients with renal impairment of varying etiology. The most common adverse experiences reported in controlled clinical trials were headache (5.2%), dizziness (4.3%), and fatigue (3.0%). In high-risk hypertensive patients, no enalapril-treated neutropenia, proteinuria, dysgeusia, or ageusia were reported. It may be concluded that the benefit-to-risk ratio of enalapril is among the best of the antihypertensive therapies currently available.
H J Gomez; V J Cirillo; S G Smith
Related Documents :
10373135 - Malnutrition and growth failure in cyanotic and acyanotic congenital heart disease with...
15028365 - Cardiovascular risk reduction in hypertensive black patients with left ventricular hype...
3560355 - Renovascular operations in patients with chronic renal insufficiency: do the benefits j...
6381895 - Hypertension in end-stage renal failure: role of sympathetic nervous system, sodium bal...
16221265 - Electrophysiologic characteristics of atria in patients without heart disease.
1866005 - Spatial contrast sensitivity is reduced in bilateral parkinson's disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  15 Suppl 3     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1990  
Date Detail:
Created Date:  1990-05-11     Completed Date:  1990-05-11     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S26-9     Citation Subset:  IM    
Department of Cardiovascular Clinical Research, Merck Sharp & Dohme Research Laboratories.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use
Enalapril / adverse effects,  therapeutic use*
Hemodynamics / drug effects
Hypertension / drug therapy*
Risk Factors
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 75847-73-3/Enalapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patient compliance and angiotensin converting enzyme inhibitors in hypertension.
Next Document:  Enalapril in the treatment of congestive heart failure.